Gabriele Escherich
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
B-cell acute lymphoblastic leukemia (B-ALL) with high-hyperdiploidy (HHD) represents the most prevalent genetic subtype of childhood ALL. This retrospective international study aimed to identify the HHD subgroup(s) having both the highest proportion of B-ALL cases and the best outcome.Data from 11,530 B-ALL patients, including 3,231 with HHD-B-ALL, treated between 1998 and 2018 in eight trials from seven international Berlin-Frankfurt-Münster Group members were analyzed. Eight HHD subgroups – including double and triple trisomies, trisomy 18, UK-good-risk (UK-GR) profile, and four different modal chromosome number (MCN) categories – were evaluated for 5-year event-free survival (EFS), overall survival, and relapse. Each subgroup was ranked by outcome measures and prevalence within the B-ALL trial cohorts.HHD frequency ranged from 19–35%. MCN 54–67 and UK-GR profile achieved the lowest overall ranking scores corresponding to the largest (up to 28% for MCN 54–67 and 26% for UK-GR among total B-ALL trial cohorts) and best HHD subgroups (EFS ranged from 80.5–92.8% for MCN 54–67 and 80.5–93.5% for UK-GR).Both an MCN of 54–67 and UK-GR profile define large, reproducible subgroups of HHD B-ALL with good prognosis. They represent strong candidates for risk-stratification of treatment de-intensification trials in the modern immunotherapy era.
Year:
2025
Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand the clinical and genetic features of this disease. We found age and genetic drivers were significantly associated with outcome. γδ T-ALL diagnosed in children under 3 years of age was extremely high-risk and enriched for genetic alterations that result in both LMO2 activation and STAG2 inactivation. Mechanistically, using patient samples and isogenic cell lines, we show that inactivation of STAG2 profoundly perturbs chromatin organization by altering enhancer–promoter looping, resulting in deregulation of gene expression associated with T-cell differentiation. High-throughput drug screening identified a vulnerability in DNA repair pathways arising from STAG2 inactivation, which can be targeted by poly(ADP-ribose) polymerase inhibition. These data provide a diagnostic framework for classification and risk stratification of pediatric γδ T-ALL. Significance: Patients with acute lymphoblastic leukemia expressing the gamma delta T-cell receptor under 3 years old or measurable residual disease ≥1% at end of induction showed dismal outcomes and should be classified as having high-risk disease. The STAG2/LMO2 subtype was enriched in this very young age group. STAG2 inactivation may perturb chromatin conformation and cell differentiation and confer vulnerability to poly(ADP-ribose) polymerase inhibition.
Year:
2024
Acute lymphoblastic leukemia (ALL) with fusions of ABL-class tyrosine kinase genes other than BCR::ABL1 occurs in ∼3% of children with ALL. The tyrosine kinase genes involved in this BCR::ABL1-like (Ph-like) subtype include ABL1, PDGFRB, ABL2, and CSF1R, each of which has up to 10 described partner genes. ABL-class ALL resembles BCR::ABL1-positive ALL with a similar gene expression profile, poor response to chemotherapy, and sensitivity to tyrosine kinase inhibitors (TKIs). There is a lack of comprehensive data regarding TKI sensitivity in the heterogeneous group of ABL-class ALL. We observed variability in TKI sensitivity within and among each ABL-class tyrosine kinase gene subgroup. We showed that ALL samples with fusions for any of the 4 tyrosine kinase genes were relatively sensitive to imatinib. In contrast, the PDGFRB-fused ALL samples were less sensitive to dasatinib and bosutinib. Variation in ex vivo TKI response within the subset of samples with the same ABL-class tyrosine kinase gene was not associated with the ALL immunophenotype, 5′ fusion partner, presence or absence of Src-homology-2/3 domains, or deletions of IKZF1, PAX5, or CDKN2A/B. In conclusion, the tyrosine kinase gene involved in ABL-class ALL is the main determinant of TKI sensitivity and relevant for specific TKI selection.
Year:
2024
Background The prognosis of children with acute lymphoblastic leukemia (ALL) has improved considerably over the past five decades. However, to achieve cure in patients with refractory or relapsed disease, novel treatment options are necessary. Methods In the multicenter trial Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (CoALL)08‐09, one additional treatment element consisting of the rarely used chemotherapeutic agent amsacrine combined with etoposide and methylprednisolone (AEP) (amsacrine 2 × 100 mg/m 2 , etoposide 2 × 500 mg/m 2 , and methylprednisolone 4 × 1000 mg/m 2 ) was incorporated into the first‐line treatment of pediatric patients with poor treatment responses at the end of induction (EOI), measured by minimal residual disease (MRD). These patients were stratified into a high‐risk intensified arm (HR‐I), including an AEP element at the end of consolidation. Patients with induction failure (IF), that is, with lack of cytomorphological remission EOI, were eligible for hematopoietic stem cell transplantation (HSCT) after remission had been reached. These patients received AEP as a part of their MRD‐guided bridging‐to‐transplant treatments. Results A significant improvement in probability of overall survival (pOS) was noted for the CoALL08‐09 HR‐I patients compared to MRD‐matched patients from the preceding CoALL07‐03 trial in the absence of severe or persistent treatment‐related toxicities. Relapse rate and probability of event‐free survival (pEFS) did not differ significantly between trials. In patients with IF, stable or improved MRD responses after AEP were observed without severe or persistent treatment‐related toxicities. Conclusion In conclusion, AEP is well tolerated as a component of the HR treatment and is useful in bridging‐to‐transplant settings.
Year:
2022
Collaborators (36)
Shondra Pruett-Miller
Associate Member
St. Jude Children's Research Hospital
Mariko Eguchi
Profesor
Ehime University Graduate School of Medicine
Chi Kong Li
Professor
The Chinese University of Hong Kong (CUHK)
Martin Schrappe
-
riccardo masetti
Assistant Professor
University of Bologna
Kjeld Schmiegelow
-
Sarah Tasian
Associate Professor
University of Pennsylvania
Hanne Vibeke Hansen Marquart
Chief Physician; MD, PhD, Clinical Associate Professor
Copenhagen University Hospital
Allen Eng Juh Yeoh
National University of Singapore (NUS)
Atsushi Manabe
Professor
Hokkaido University
Valentino Conter
-
John Choi
The University of Alabama
Anthony Moorman
Professor of Genetic Epidemiology
Newcastle University
Franco Locatelli
Full Professor of Pediatrics
Catholic University of the Sacred Heart
Steven Kornblau
Professor
The University of Texas MD Anderson Cancer Center
Junko Takita
教授 / Professor
Kyoto University
Szymon Skoczen
Associated Professor
Uniwersytet Jagiellonski Collegium Medicum
Kathryn Roberts
St. Jude Children's Research Hospital
David Teachey
Professor
Children's Hospital of Philadelphia
Daisuke Tomizawa
Head
National Center For Child Health and Development
Cheng Cheng
Professor
St Jude Grade School of Biomedical Sciences
Arndt Borkhardt
Prof
Heinrich Heine University Düsseldorf
Motohiro Kato
-
Judith Boer
Senior researcher
Princess Maxima Center
Takao Deguchi
Head of Division
National Center For Child Health and Development
Monique den Boer
Group Leader
Princess Maxima Center
Ching-Hon Pui
Fahad Nasser Al-Rashid Chair of Leukemia Research
St. Jude Children's Research Hospital
Andrew Moore
Associate Professor
University of Queensland
Ilaria Iacobucci
Principal Scientist
St. Jude Children's Research Hospital
Masatoshi Takagi
Tokyo Medical and Dental University
Zhaohui Gu
Assistant Professor
Beckman Research Institute, City of Hope
Paul G Thomas
Professor
Fred Hutch Cancer Center
Andishe Attarbaschi
Medical University of Vienna
Amir Enshaei
Senior Lecturer
Newcastle University
Charles Mullighan
Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center
St. Jude Children's Research Hospital
Rishi Kotecha
Professor
Telethon Kids Institute
Make your next move.
Prepare your application
Review drafts before you send them.